• 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
  • 2
    Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Handbook. 6th ed. New York, NY: Springer-Verlag; 2002.
  • 3
    Greene FL, Stewart AK, Norton HJ. New tumor-node-metastasis staging strategy for node-positive (stage III) rectal cancer: an analysis. J Clin Oncol. 2004; 22: 1778-1784.
  • 4
    Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005; 352: 476-487.
  • 5
    Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22: 1209-1214.
  • 6
    Wood KW, Sarnecki C, Roberts TM, Blenis J. ras mediates nerve growth factor receptor modulation of 3 signal-transducing protein kinases: Map kinase, Raf-1, and RSK. Cell. 1992; 68: 1041-1050.
  • 7
    Leevers SJ, Marshall CJ. Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein. EMBO J. 1992; 11: 569-574.
  • 8
    Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 1994; 370: 527-532.
  • 9
    Hofer F, Fields S, Schneider C, Martin GS. Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator. Proc Natl Acad Sci USA. 1994; 91: 11089-11093.
  • 10
    Spaargaren M, Bischoff JR. Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-ras, K-ras, and Rap. Proc Natl Acad Sci U S A. 1994; 91: 12609-12613.
  • 11
    Marte BM, Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci. 1997; 22: 355-358.
  • 12
    Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 1997; 16: 2783-2793.
  • 13
    Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008; 9: 517-531.
  • 14
    Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature. 1993; 366: 643-654.
  • 15
    Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol. 1999; 17: 3631-3652.
  • 16
    Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987; 327: 293-297.
  • 17
    Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987; 327: 298-303.
  • 18
    Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res. 1992; 52( 9 suppl): 2665s-2669s.
  • 19
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61: 759-767.
  • 20
    Smith G, Carey FA, Beattie J, et al. Mutations in APC, Kirsten-ras, and p53–alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA. 2002; 99: 9433-9438.
  • 21
    Giaretti W, Venesio T, Sciutto A, Prevosto C, Geido E, Risio M. Near-diploid and near-triploid human sporadic colorectal adenocarcinomas differ for KRAS2 and TP53 mutational status. Genes Chromosomes Cancer. 2003; 37: 207-213.
  • 22
    Giaretti W, Venesio T, Prevosto C, et al. Chromosomal instability and APC gene mutations in human sporadic colorectal adenomas. J Pathol. 2004; 204: 193-199.
  • 23
    Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst. 1998; 90: 675-684.
  • 24
    Shivapurkar N, Huang L, Ruggeri B, et al. K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients. Cancer Lett. 1997; 115: 39-46.
  • 25
    Yuan P, Sun MH, Zhang JS, Zhu XZ, Shi DR. APC and K-ras gene mutation in aberrant crypt foci of human colon. World J Gastroenterol. 2001; 7: 352-356.
  • 26
    Calcagno SR, Li S, Colon M, et al. Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon. Int J Cancer. 2008; 122: 2462-2470.
  • 27
    Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319: 525-532.
  • 28
    Kern SE, Fearon ER, Tersmette KW, et al. Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. JAMA. 1989; 261: 3099-3103.
  • 29
    Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science. 1989; 244: 207-211.
  • 30
    Smakman N, Borel Rinkes IH, Voest EE, Kranenburg O. Control of colorectal metastasis formation by K-Ras. Biochim Biophys Acta. 2005; 1756: 103-114.
  • 31
    Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3: 11-22.
  • 32
    Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 2001; 61: 6050-604.
  • 33
    Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005; 97: 981-989.
  • 34
    Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005; 23: 3502-358.
  • 35
    Yamamoto H, Itoh F, Senota A, et al. Expression of matrix metalloproteinase matrilysin (MMP-7) was induced by activated Ki-ras via AP-1 activation in SW1417 colon cancer cells. J Clin Lab Anal. 1995; 9: 297-301.
  • 36
    Jankun J, Maher VM, McCormick JJ. Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator. Cancer Res. 1991; 51: 1221-126.
  • 37
    Allgayer H, Wang H, Shirasawa S, Sasazuki T, Boyd D. Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. Br J Cancer. 1999; 80: 1884-1891.
  • 38
    Buo L, Meling GI, Karlsrud TS, Johansen HT, Aasen AO. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol. 1995; 26: 1133-118.
  • 39
    Pollock CB, Shirasawa S, Sasazuki T, Kolch W, Dhillon AS. Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res. 2005; 65: 1244-1250.
  • 40
    Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘;RASCAL II’ study. Br J Cancer. 2001; 85: 692-696.
  • 41
    Finkelstein SD, Sayegh R, Christensen S, Swalsky PA. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer. 1993; 71: 3827-3838.
  • 42
    Esteller M, Gonzalez S, Risques RA, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol. 2001; 19: 299-304.
  • 43
    Andreyev HJ, Tilsed JV, Cunningham D, et al. K-ras mutations in patients with early colorectal cancers. Gut. 1997; 41: 323-329.
  • 44
    Font A, Abad A, Monzo M, et al. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum. 2001; 44: 549-557.
  • 45
    Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005; 54: 1283-126.
  • 46
    Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 2000; 9: 1193-117.
  • 47
    Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol. 2002; 13: 1438-1446.
  • 48
    Messa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 1998; 37: 285-289.
  • 49
    Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000; 21: 105-115.
  • 50
    Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993; 71: 2454-2460.
  • 51
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-345.
  • 52
    Van Cutsem E, Geboes K. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Best Pract Res Clin Gastroenterol. 2007; 21: 1089-1108.
  • 53
    Personeni N, De Schutter J, De Hertogh G, al. E. Response prediction to cetuximab-based therapy: the role of EGFR copy number by fluorescence in situ hybridization and downstream effectors gene mutations. 2007 Gastrointestinal Cancers Symposium. 2007: 400.
  • 54
    Finocchiaro G, Cappuzzo F, Janne PA, et al. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer [abstract]. J Clin Oncol. 2007; 25( suppl). Abstract 4021.
  • 55
    De Rook W, De Schutter J, De Hertogh G, et al. KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab [abstract]. J Clin Oncol. 2007; 25. Abstract 4132.
  • 56
    De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008; 19: 508-515.
  • 57
    Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 1626-1634.
  • 58
    Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359: 1757-1765.
  • 59
    Viret F, Smedra BT, Esteyries S, et al. Genetic predictors of cetuximab response in metastatic colorectal cancer. 2008 Gastrointestinal Cancers Symposium. 2008: 438.
  • 60
    Stoehlmacher J, Mogck U, Jakob C, et al. KRAS mutations, EGFR polymorphisms, and polymorphisms of immunoglobulin fragment C receptor as predictors for response to cetuximab containing chemotherapy in colorectal cancer patients. Identification of new KRAS mutation in codon12. 2008 Gastrointestinal Cancers Symposium. 2008: 410.
  • 61
    Bokeneyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience [abstract]. J Clin Oncol. 2008; 26( suppl): Abstract 4000.
  • 62
    Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [abstract]. J Clin Oncol. 2008; 26( suppl): Abstract 2.
  • 63
    Tejpar S PM, Humblet Y, et al. Relationship of efficacy with KRAS status (wild type vs mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) [abstract]. J Clin Oncol. 2008; 26( suppl): Abstract 4001.
  • 64
    Loupakis F, Pollina L, Stasi G, et al. Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment [abstract]. J Clin Oncol. 2008; 26( suppl): Abstract 4003.
  • 65
    Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate. 2008; 68: 935-944.
  • 66
    Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-954.
  • 67
    Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PIK (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer. 2008; 122: 2255-229.
  • 68
    Amado RG, Wolf M, Freeman D, al. e. Panitumumab (pmab) efficacy and patient-reported outcomes (PRO) in metastatic colorectal cancer (mCRC) patients (pts) with wild-type (WT) KRAS tumor status. 2008 Gastrointestinal Cancers Symposium. 2008: 278.